A Phase 3 interventional study of dutasteride 0.5mg once daily for 4 years and tamsulosin 0.4mg once daily for 4 years in Prostatic Hyperplasia, sponsored by GlaxoSmithKline. Completed at 504 sites in 36 countries. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-02-28.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing dutasteride in Prostatic Hyperplasia — 1 open to participants now, 1 under way, none of them phase 3. Dutasteride · Prostatic Hyperplasia.
Among the 27 studies testing dutasteride in Prostatic Hyperplasia, this one has the largest enrollment, is one of 3 that started in 2003, is one of 4 in phase 3, and was the 2nd registered.
828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.
Browse Prostatic Hyperplasia studies →1 of the 27 studies testing dutasteride in Prostatic Hyperplasia is open now, in 1 country. Recruiting first, the newest first:
Mohamed Mahmoud Dogha · Sites in Egypt
Ages 50+ · Men only
By country, each count listing its studies:
Dutasteride: first FDA approval 2001 (AVODART). What it is approved for, and how studies give it, is on its page →
Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,844 is above the median of 92 across 627 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 44 across the 27 interventional studies. Of the 24 that completed or were terminated, 8 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 27 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
43 studies in Prostatic Hyperplasia by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 43 finished, 17 (40%) have results posted.
Among the 43 studies in Prostatic Hyperplasia by GlaxoSmithKline, this one has the largest enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2003, is one of 5 in phase 3, and was the 2nd registered.
GlaxoSmithKline’s Prostatic Hyperplasia studies by the year they started, since 2003.
1 of the studies testing dutasteride in Prostatic Hyperplasia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07911501Mohamed Mahmoud DoghaPerioperative Dutasteride for Hemorrhage Control in Bipolar TURP Under Anticoagulation. | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies testing dutasteride in Prostatic Hyperplasia, from their registry updates:
Among GlaxoSmithKline’s 43 in Prostatic Hyperplasia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will investigate the efficacy and safety of treatment with dutasteride and tamsulosin, administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic Benign Prostatic Hyperplasia (BPH). Study visits are every 3 months for up to 4 years (18 clinic visits). Transrectal ultrasound (TRUS) is done annually.
A randomised, double-blind, parallel group study to investigate the efficacy and safety of treatment with Dutasteride (0.5 mg) and Tamsulosin (0.4 mg), administered once daily for 4 years, alone and in combination, on the improvement of symptoms and clinical outcome in men with moderate to severe symptomatic benign prostatic hyperplasia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Note: If total serum PSA is >4ng/mL and unless PSA value has been stable for at least the past 2 years, the investigator should make every appropriate effort to exclude the possibility of prostate cancer, e.g. further DRE, review TRUS taken within previous month, consider 8-12 core prostate biopsy in accordance with routine clinical practice.
Note: the purpose of this criteria is to be able to standardise baseline symptom severity for all enrolled patients prior to randomisation and not to specifically exclude current alpha-adrenoreceptor blocker users from participation in the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dutasteride 0.5mg once daily
Drug: dutasteride 0.5mg once daily for 4 years
Combination of dutasteride (0.5mg) and tamsulosin (0.4mg), once daily
Drug: dutasteride 0.5mg once daily for 4 years · Drug: tamsulosin 0.4mg once daily for 4 years
tamsulosin 0.4mg once daily
Drug: tamsulosin 0.4mg once daily for 4 years
combination or single agent
combination agent or single agent
Also known as: dutasteride, tamsulosin
Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.
A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant-reported or identified, they were recorded in the participants' clinic record.
Time frame: Years 1, 2, 3, and 4
Number of Participants With AUR or BPH-related Surgery
A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant reported or identified, they were recorded in the participants' clinic record.
Time frame: Baseline (Day 1) through Year 4
Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4
The time when the first symptom/event of BPH clinical progression has occurred (i.e. AUR, incontinence) was measured. Summaries are based on the first occuring event after treatment start. The time period is from treatment start to each participant's last treatment visit. The Year 4 events include all those that occur during the fourth year and beyond.
Time frame: Years 1, 2, 3, and 4
The Number of Participants With Each of the Five Components of BPH Clinical Progression
The five components measured were symptom deterioration, BPH-related AUR, BPH-related incontinence, recurrent BPH-related Urinary Tract Infection (UTI), and BPH-related renal insufficiency.
Time frame: Baseline (Day 1) to Year 4
Number of Events of Symptom Deterioration at the Indicated Time Periods
The number of participants (par.) with symptom deterioration of International Prostate Symptom Score (IPSS) ≥4 points on two consecutive visits post-baseline are presented. Data are based on the first occurrence of an event after treatment start. The year-4 events include all that occured during the 4th year and beyond. The IPSS is a 7-item questionnaire measuring the level of urinary symptoms reported as the total score. Each question has a 6-point response scale (0=none/not at all to 5=almost always), with a total score ranging from 0-35: mild (0-7), moderate (8-19), or severe (20-35).
Time frame: Years 1, 2, 3, and 4 (from treatment start until each participant's last treatment-phase visit)
Number of Participants With an Event of Post-baseline BPH-related Macroscopic Hematuria
A participant was considered to have macroscopic hematuria when there was presence of blood in the urine. The event of macroscopic hematuria was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related macroscopic hematuria. Participants may appear in both categories.
Time frame: Baseline (Day 1) through Year 4
Number of Participants With an Event of Post-baseline BPH-related Hematospermia
A participant was considered to have hematospermia when there was presence of blood in the semen. Hematospermia can occur from prostatitis (prostate infection), from cancer, or after a prostate biopsy. The event of hematospermia was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related hematospermia. Participants may appear in both categories.
Time frame: Baseline (Day 1) through Year 4
Adjusted Mean Change From Baseline in International Prostate Symptom Score (IPSS) at Months 12, 24, 36, and 48
The IPSS is a 7-item questionnaire that measures urinary symptoms. It measures the level of urinary symptoms (including incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia) reported as the total IPSS score. Each of the 7 questions has a 6-point response scale (0=none/not at all to 5=almost always) with a total score that can range from 0-35: mild (0-7), moderate (8-19), or severe (20-35). Estimates are based on adjusted (least squares) means from the general linear model: change from baseline IPSS = Treatment + Cluster + Baseline IPSS.
Time frame: Baseline and Months 12, 24, 36, and 48
Adjusted Mean Change From Baseline in Urinary Flow Rate (Qmax) at Months 12, 24, 36, and 48
Peak maximum urinary flow (Qmax) of urinary flow using a Medtronic (formerly Dantec) Uroflow Meter (Urodyn 1000 or Duet models) with a Thompson filter was measured. Estimates are based on adjusted (least squares) means from the general linear model: Change from baseline Qmax = treatment + cluster + baseline Qmax.
Time frame: Baseline and Months 12, 24, 36, and 48
Adjusted Mean Percent Change From Baseline in Prostate Volume at Months 12, 24, 36, and 48
Prostate volume measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total prostate volume centimeters (cc). Percent change from baseline = \[(post-baseline - baseline)/baseline value\] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: log(post-baseline/baseline value) + treatment + cluster + log(baseline value) and are reported as percent change from baseline.
Time frame: Baseline and Months 12, 24, 36, and 48
Adjusted Mean Change From Baseline in Transition Zone (Portion of the Prostate That Surrounds the Proximal Urethra) Volume at Months 12, 24, 36, and 48
Prostate volume (PV) measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total PV in centimeters (cc). Results are for the transition zone measurements of the prostate in a small subset of participants. Percent change from baseline (BL) = \[(post-BL - BL)/BL value\] x 100. Estimates are based on the adjusted (least squares) means for the general linear model: log(post-BL/BL value) = treatment + cluster + log(BL value) and are reported as percent change from BL.
Time frame: Baseline and Months 12, 24, 36, and 48
Number of Unscheduled Visits to GP/Urologist Regarding AUR Symptoms Since the Last Study Visit
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: "Has the participant needed to make any unscheduled visits to his general practitioner (GP)/Urologist regarding AUR symptoms since the last study visit?" If the answer to the question was "yes," the number of visits was recorded.
Time frame: Every 3 months from Month 3 to Month 48
Number of "Yes" Responses to the Question: "Would the Participant Have Paid a Visit to His GP/Urologist Regarding AUR Symptoms if the Study Visit Had Not Been Planned"?.
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: "Would the participant have paid a visit to his GP/Urologist regarding AUR symptoms if this study visit had not been planned?". If the answer to the question was "yes," the number of Yes responses was recorded.
Time frame: Every 3 months from Month 3 to Month 48
Number of Visits to GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: "Has the participant needed to visit his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?". If the answer to the question was "yes," the number of visits was recorded.
Time frame: Every 3 months from Month 3 to Month 48
Number of "Yes" Responses to the Question: "Would the Participant Have Paid a Visit to His GP/Urologist Regarding BPH-related Surgery Since the Last Study Visit?"
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: "Would the participant have paid a visit to his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?". If the answer to the question was "yes," the number of Yes responses was recorded.
Time frame: Every 3 months from Month 3 to Month 48
Number of Unplanned Visits to GP/Urologist That Would Have Taken Place if a Scheduled Study Visit Had Not Been Planned (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: "Has the participant had any unplanned GP/Urologist (outpatient) visits that would have taken place if a scheduled study visit had not been planned (this can include visits resulting from UTI, UI macroscopic haematuria, etc?". If the answer to the question was "yes," the number of visits was recorded.
Time frame: Every 3 months from Month 3 to Month 48
Number of Unscheduled Visits to GP/Urologist (Outpatient) Planned, Not Relating to the Study (Including Visits Resulting From UTI, UI, Macroscopic Haematuria, Etc.)
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: "Does the participant have any unscheduled GP/Urologist (outpatients) visits planned, not relating to the study (this can include visits resulting from UTI, UI, macroscopic haematuria, etc.?". If the answer to the question was "yes," the number of visits was recorded.
Time frame: Every 3 months from Month 3 to Month 48
Adjusted Mean Change From Baseline in BPH Impact Index (BII) at Months 12, 24, 36, and 48
The BII is a 4-item questionnaire, score range of 0 (best) to 12 (worst) for questions 1-3, and 0 (best) to 13 (worst) for question 4, that assesses the overall impact of BPH on a participant's general sense of well being and measures aspects of physical discomfort, worry, and bother, all of which can be affected by BPH and its symptoms. BII score = sum of questions 1-4. Change from baseline = Post-Baseline Value. Estimates are based on the adjusted (least squares) means from the general linear model: change from baseline BII = treatment + cluster + baseline BII.
Time frame: Baseline and Months 12, 24, 36, and 48
Adjusted Mean Change From Baseline in BPH-Related Health Status (BHS) at Months 12, 24, 36, and 48
The effect of study treatment on BHS was assessed by using three self-administered questionnaires: the International Prostate Symptom Score (IPSS), the BPH Impact Index (BII), and Patient Perception of Study Medication (PPSM). The BHS score was collected on the IPPS questionnaire and ranged from 0 (best) to 6 (worst). Percent change from baseline = \[(post-baseline - baseline)/baseline value\] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: change from baseline BPH-related health status = treatment + cluster + baseline BPH-Related health status.
Time frame: Baseline and Months 12, 24, 36, 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 1 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has control of your urinary problems changed?".
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 2 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect of the study medication on control of your urinary problems?" Satisfact., satisfaction.
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 3 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has the strength of your urinary stream changed?".
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 4 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect of the study medication on the strength of your urinary stream?". Satisfact., satisfaction.
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 5 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has your pain prior to urinating changed?".
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 6 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your pain prior to urinating?". Satisfact., satisfaction.
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 7 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has your pain during urination changed?".
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 8 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your pain during urination?". Satisfact., satisfaction.
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 9 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has the way your urinary problems interfere with your ability to go about your usual activities changed?".
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 10 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your ability to go about your usual activities without interference from your urinary problems?". Satisfact., satisfaction.
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 11 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Overall, how satisfied are you with the study medication and it's effect on your urinary problems?". Satisfact., satisfaction.
Time frame: Baseline and Months 12, 24, 36, and 48
Patient Perception of Study Medication (PPSM): Number of Participants With the Indicated Responses to Question 12 (LOCF)
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Would you ask your doctor for the medication you received in this study?".
Time frame: Baseline and Months 12, 24, 36, and 48
| Milestone | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Started | 1610 | 1623 | 1611 |
| Completed | 1113 | 1093 | 989 |
| Not completed | 497 | 530 | 622 |
| Withdrew: Adverse event | 211 | 185 | 210 |
| Withdrew: Withdrawal by subject | 114 | 160 | 148 |
| Withdrew: Lost to follow-up | 53 | 48 | 58 |
| Withdrew: Protocol violation | 29 | 29 | 34 |
| Withdrew: Lack of efficacy | 53 | 71 | 104 |
| Withdrew: Participant relocated | 7 | 2 | 8 |
| Withdrew: Site closed/sponsor termination | 7 | 7 | 4 |
| Withdrew: Non-compliant/medication interruption | 6 | 4 | 7 |
| Withdrew: Prostate surgery/turp/alt. therapy | 3 | 7 | 19 |
| Withdrew: Participant decision/withdrawn | 2 | 0 | 4 |
| Withdrew: Acute urinary retention (aur) | 2 | 3 | 6 |
| Withdrew: Prohibited medication | 2 | 2 | 8 |
| Withdrew: Investigator departure | 2 | 0 | 0 |
| Withdrew: Alcohol dependent | 1 | 0 | 0 |
| Withdrew: Screen failure | 1 | 0 | 0 |
| Withdrew: No improvement | 1 | 0 | 0 |
| Withdrew: Bph/bph symptoms worse/urinary incont. | 1 | 0 | 5 |
| Withdrew: Financial problems | 1 | 0 | 0 |
| Withdrew: Loss of libido | 1 | 0 | 0 |
| Withdrew: Angina pectoris | 0 | 2 | 0 |
| Withdrew: Loss of contact | 0 | 1 | 0 |
| Withdrew: Neoplasm of bladder/prostate | 0 | 1 | 1 |
| Withdrew: Cardiologist/neurologist decision | 0 | 2 | 0 |
| Withdrew: Renal insufficiency | 0 | 1 | 0 |
| Withdrew: Back pain | 0 | 1 | 0 |
| Withdrew: Scheduling issues | 0 | 1 | 0 |
| Withdrew: Any appreciable improvement | 0 | 1 | 0 |
| Withdrew: Investigator decision | 0 | 1 | 3 |
| Withdrew: Enrollment error | 0 | 0 | 2 |
| Withdrew: Urinary tract infection (uti) | 0 | 0 | 1 |
| Withdrew: Prostate specific antigen rising | 0 | 1 | 0 |
| Milestone | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Started | 1598 | 1615 | 1600 |
| Completed | 1224 | 1205 | 1143 |
| Not completed | 374 | 410 | 457 |
| Withdrew: Adverse event | 34 | 39 | 44 |
| Withdrew: Withdrawal by subject | 185 | 212 | 229 |
| Withdrew: Lost to follow-up | 101 | 97 | 111 |
| Withdrew: Protocol violation | 18 | 18 | 17 |
| Withdrew: Site closed/sponsor termination | 8 | 5 | 4 |
| Withdrew: Non-compliant/medication interruption | 8 | 6 | 4 |
| Withdrew: Loss of contact | 4 | 0 | 2 |
| Withdrew: Disease progression/treatment failure | 3 | 1 | 1 |
| Withdrew: Participant relocated | 2 | 3 | 1 |
| Withdrew: Participant decision/withdrawn | 2 | 1 | 2 |
| Withdrew: Prohibited medication | 2 | 3 | 5 |
| Withdrew: Alcohol dependent | 1 | 0 | 1 |
| Withdrew: Prostate surgery/turp/alt. therapy | 1 | 5 | 13 |
| Withdrew: Loss of libido | 1 | 0 | 0 |
| Withdrew: Enrollment error | 1 | 0 | 2 |
| Withdrew: Neoplasm of bladder/prostate cancer | 1 | 3 | 6 |
| Withdrew: Death | 1 | 0 | 1 |
| Withdrew: Gyneomastia | 1 | 0 | 0 |
| Withdrew: Acute urinary retention (aur) | 0 | 5 | 4 |
| Withdrew: Bph/bph symptoms worse/urinary incont. | 0 | 2 | 3 |
| Withdrew: Angina pectoris | 0 | 1 | 0 |
| Withdrew: Back pain | 0 | 1 | 0 |
| Withdrew: Scheduling issues | 0 | 2 | 4 |
| Withdrew: Investigator/sponsor decision | 0 | 2 | 3 |
| Withdrew: Depression | 0 | 1 | 0 |
| Withdrew: Diabetes uncontrolled | 0 | 1 | 0 |
| Withdrew: Jailed | 0 | 1 | 0 |
| Withdrew: Other | 0 | 1 | 0 |
A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant-reported or identified, they were recorded in the participants' clinic record.
| events | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Year 1, n=1610, 1623, 1611 | 29 | 27 | 40 |
| Year 2, n=1457, 1484, 1464 | 14 | 22 | 62 |
| Year 3, n=1347, 1365, 1307 | 15 | 16 | 44 |
| Year 4, n=1274, 1277, 1176 | 9 | 19 | 45 |
The time when the first symptom/event of BPH clinical progression has occurred (i.e. AUR, incontinence) was measured. Summaries are based on the first occuring event after treatment start. The time period is from treatment start to each participant's last treatment visit. The Year 4 events include all those that occur during the fourth year and beyond.
| events | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Year 1, n=1610, 1623, 1611 | 126 | 184 | 171 |
| Year 2, n= 1264, 1240, 1262 | 31 | 54 | 78 |
| Year 3, n=1135, 1082, 1048 | 30 | 29 | 67 |
| Year 4, n= 1047, 959, 880 | 16 | 22 | 31 |
A participant was considered to have AUR when he was unable to urinate and required bladder catheterization. BPH is also known as an enlarged prostate. When symptoms of BPH become bothersome, surgery may be required. When events of AUR and BPH-related surgery were participant reported or identified, they were recorded in the participants' clinic record.
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| AUR | 35 | 44 | 109 |
| BPH-related surgery | 32 | 40 | 82 |
The five components measured were symptom deterioration, BPH-related AUR, BPH-related incontinence, recurrent BPH-related Urinary Tract Infection (UTI), and BPH-related renal insufficiency.
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Symptom deterioration | 132 | 203 | 221 |
| BPH-related AUR | 22 | 31 | 64 |
| BPH-related incontinence | 46 | 49 | 56 |
| Recurrent BPH-related UTI | 2 | 5 | 3 |
| BPH-related renal insufficiency | 1 | 2 | 5 |
The number of participants (par.) with symptom deterioration of International Prostate Symptom Score (IPSS) ≥4 points on two consecutive visits post-baseline are presented. Data are based on the first occurrence of an event after treatment start. The year-4 events include all that occured during the 4th year and beyond. The IPSS is a 7-item questionnaire measuring the level of urinary symptoms reported as the total score. Each question has a 6-point response scale (0=none/not at all to 5=almost always), with a total score ranging from 0-35: mild (0-7), moderate (8-19), or severe (20-35).
| events | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Year 1, n=1610, 1623, 1611 | 91 | 138 | 119 |
| Year 2, n=1286, 1278, 1296 | 23 | 38 | 49 |
| Year 3, n=1158, 1132, 1088 | 14 | 23 | 42 |
| Year 4, n=1083, 1001, 926 | 11 | 13 | 19 |
A participant was considered to have macroscopic hematuria when there was presence of blood in the urine. The event of macroscopic hematuria was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related macroscopic hematuria. Participants may appear in both categories.
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Overall crude rate | 53 | 70 | 81 |
| Non-BPH-related Crude Rate | 15 | 28 | 25 |
| BPH-Related Crude Rate | 40 | 45 | 56 |
A participant was considered to have hematospermia when there was presence of blood in the semen. Hematospermia can occur from prostatitis (prostate infection), from cancer, or after a prostate biopsy. The event of hematospermia was either participant-reported or identified by the investigator during a clinic visit. Overall Crude Rate is the number of participants from the total number analyzed that experience experienced an incident of post-baseline BPH or Non-BPH related hematospermia. Participants may appear in both categories.
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Overall Crude Rate | 18 | 19 | 20 |
| Non-BPH-related Crude Rate | 2 | 3 | 9 |
| BPH-related Crude Rate | 17 | 17 | 11 |
The IPSS is a 7-item questionnaire that measures urinary symptoms. It measures the level of urinary symptoms (including incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia) reported as the total IPSS score. Each of the 7 questions has a 6-point response scale (0=none/not at all to 5=almost always) with a total score that can range from 0-35: mild (0-7), moderate (8-19), or severe (20-35). Estimates are based on adjusted (least squares) means from the general linear model: change from baseline IPSS = Treatment + Cluster + Baseline IPSS.
| points on a scale | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 12 | -5.6 ± 0.15 | -4.2 ± 0.15 | -4.5 ± 0.15 |
| Month 24 | -6.2 ± 0.15 | -4.9 ± 0.15 | -4.3 ± 0.15 |
| Month 36 | -6.3 ± 0.16 | -5.2 ± 0.16 | -4.0 ± 0.16 |
| Month 48 | -6.3 ± 0.16 | -5.3 ± 0.16 | -3.8 ± 0.16 |
Peak maximum urinary flow (Qmax) of urinary flow using a Medtronic (formerly Dantec) Uroflow Meter (Urodyn 1000 or Duet models) with a Thompson filter was measured. Estimates are based on adjusted (least squares) means from the general linear model: Change from baseline Qmax = treatment + cluster + baseline Qmax.
| milliliters (mL)/second (sec) | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 12, n=1477, 1482, 1510 | 2.0 ± 0.12 | 1.5 ± 0.12 | 0.9 ± 0.12 |
| Month 24, n= 1492, 1501, 1519 | 2.4 ± 0.12 | 1.9 ± 0.12 | 0.9 ± 0.12 |
| Month 36, n= 1495, 1504, 1521 | 2.6 ± 0.12 | 1.9 ± 0.12 | 0.6 ± 0.12 |
| Month 48, n= 1495, 1505, 1523 | 2.4 ± 0.13 | 2.0 ± 0.13 | 0.7 ± 0.13 |
Prostate volume measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total prostate volume centimeters (cc). Percent change from baseline = \[(post-baseline - baseline)/baseline value\] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: log(post-baseline/baseline value) + treatment + cluster + log(baseline value) and are reported as percent change from baseline.
| percent change | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 12, n=1411, 1442, 1451 | -24.1 ± 0.60 | -25.2 ± 0.59 | -1.5 ± 0.77 |
| Month 24, n= 1427, 1451, 1465 | -26.9 ± 0.62 | -28.0 ± 0.61 | 0.0 ± 0.84 |
| Month 36, n= 1430, 1455, 1468 | -27.6 ± 0.68 | -28.8 ± 0.66 | 1.6 ± 0.94 |
| Month 48, n= 1430, 1455, 1468 | -27.3 ± 0.66 | -28.0 ± 0.65 | 4.6 ± 0.94 |
Prostate volume (PV) measurements were conducted annually using Transurethral ultrasound (TRUS). The anteroposterior, cephalocaudal, and transverse diameters of the prostate obtained by TRUS calculate the total PV in centimeters (cc). Results are for the transition zone measurements of the prostate in a small subset of participants. Percent change from baseline (BL) = \[(post-BL - BL)/BL value\] x 100. Estimates are based on the adjusted (least squares) means for the general linear model: log(post-BL/BL value) = treatment + cluster + log(BL value) and are reported as percent change from BL.
| percent change | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 12, n= 150, 159, 160 | -17.2 ± 3.29 | -15.6 ± 3.39 | 5.6 ± 4.09 |
| Month 24, n= 153, 164, 160 | -23.4 ± 5.63 | -22.8 ± 5.86 | 8.7 ± 8.22 |
| Month 36, n= 155, 164, 162 | -20.9 ± 3.97 | -26.7 ± 3.90 | 14.7 ± 5.89 |
| Month 48, n= 155, 164, 163 | -17.9 ± 4.45 | -26.5 ± 4.21 | 18.2 ± 6.54 |
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: "Has the participant needed to make any unscheduled visits to his general practitioner (GP)/Urologist regarding AUR symptoms since the last study visit?" If the answer to the question was "yes," the number of visits was recorded.
| visits | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 3, n=1550, 1581, 1565 | 8 | 6 | 7 |
| Month 6, n=1479, 1517, 1514 | 2 | 4 | 3 |
| Month 9, n=1439, 1465, 1477 | 4 | 3 | 8 |
| Month 12, n=1400, 1431, 1434 | 3 | 3 | 9 |
| Month 15, n=1343, 1386, 1380 | 3 | 6 | 6 |
| Month 18, n=1318, 1350, 1328 | 3 | 4 | 10 |
| Month 21, n=1281, 1326, 1287 | 3 | 3 | 9 |
| Month 24, n=1263, 1293, 1244 | 2 | 2 | 7 |
| Month 27, n=1233, 1262, 1206 | 1 | 6 | 7 |
| Month 30, n=1222, 1221, 1166 | 3 | 2 | 8 |
| Month 33, n=1202, 1199, 1128 | 3 | 4 | 5 |
| Month 36, n=1187, 1174, 1095 | 2 | 1 | 5 |
| Month 39, n=1160, 1144, 1055 | 2 | 2 | 5 |
| Month 42, n=1149, 1126, 1035 | 3 | 2 | 8 |
| Month 45, n=1129, 1110, 1009 | 1 | 2 | 4 |
| Month 48, n=1113, 1093, 990 | 1 | 2 | 2 |
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with an episode of AUR. Responses to the following question were recorded: "Would the participant have paid a visit to his GP/Urologist regarding AUR symptoms if this study visit had not been planned?". If the answer to the question was "yes," the number of Yes responses was recorded.
| yes responses | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 3, n=1550, 1581, 1564 | 31 | 32 | 29 |
| Month 6, n=1479, 1516, 1513 | 21 | 26 | 26 |
| Month 9, n=1439, 1465, 1477 | 18 | 14 | 18 |
| Month 12, n=1400, 1431, 1434 | 8 | 13 | 9 |
| Month 15, n=1343, 1386, 1380 | 9 | 15 | 12 |
| Month 18, n=1318, 1350, 1328 | 17 | 13 | 19 |
| Month 21, n=1281, 1326, 1287 | 10 | 15 | 17 |
| Month 24, n=1263, 1293, 1244 | 5 | 9 | 8 |
| Month 27, n=1233, 1262, 1206 | 9 | 11 | 8 |
| Month 30, n=1222, 1221, 1166 | 7 | 9 | 9 |
| Month 33, n=1202, 1199, 1128 | 9 | 10 | 11 |
| Month 36, n=1187, 1174, 1095 | 5 | 4 | 5 |
| Month 39, n=1160, 1144, 1055 | 7 | 9 | 6 |
| Month 42, n=1149, 1126, 1035 | 6 | 8 | 8 |
| Month 45, n=1129, 1110, 1009 | 7 | 8 | 5 |
| Month 48, n=1113, 1093, 990 | 2 | 9 | 5 |
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: "Has the participant needed to visit his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?". If the answer to the question was "yes," the number of visits was recorded.
| visits | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 3, n=1550, 1581, 1564 | 0 | 3 | 3 |
| Month 6, n=1479, 1517, 1514 | 2 | 1 | 2 |
| Month 9, n=1439, 1465, 1477 | 2 | 2 | 3 |
| Month 12, n=1400, 1431, 1434 | 1 | 2 | 7 |
| Month 15, n=1343, 1386, 1380 | 2 | 5 | 7 |
| Month 18, n=1318, 1350, 1328 | 4 | 0 | 4 |
| Month 21, n=1281, 1326, 1287 | 1 | 0 | 3 |
| Month 24, n=1263, 1293, 1244 | 2 | 0 | 3 |
| Month 27, n=1233, 1262, 1206 | 3 | 3 | 4 |
| Month 30, n=1222, 1221, 1165 | 0 | 1 | 1 |
| Month 33, n=1202, 1199, 1128 | 0 | 1 | 5 |
| Month 36, n=1187, 1174, 1095 | 2 | 2 | 1 |
| Month 39, n=1160, 1144, 1055 | 1 | 3 | 2 |
| Month 42, n=1149, 1126, 1035 | 1 | 2 | 5 |
| Month 45, n=1129, 1110, 1009 | 0 | 3 | 2 |
| Month 48, n=1113, 1093, 990 | 0 | 2 | 1 |
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with BPH-related surgery. Responses to the following question were recorded: "Would the participant have paid a visit to his general practitioner (GP)/Urologist regarding BPH-related surgery since the last study visit?". If the answer to the question was "yes," the number of Yes responses was recorded.
| yes responses | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 3, n=1550, 1581, 1564 | 16 | 34 | 28 |
| Month 6, n=1479, 1516, 1513 | 20 | 23 | 16 |
| Month 9, n=1438, 1465, 1477 | 12 | 10 | 17 |
| Month 12, n=1400, 1431, 1434 | 5 | 10 | 6 |
| Month 15, n=1343, 1386, 1380 | 9 | 9 | 9 |
| Month 18, n=1318, 1350, 1328 | 13 | 12 | 10 |
| Month 21, n=1281, 1326, 1287 | 10 | 9 | 8 |
| Month 24, n=1263, 1293, 1244 | 4 | 7 | 3 |
| Month 27, n=1233, 1262, 1206 | 9 | 9 | 5 |
| Month 30, n=1222, 1221, 1166 | 7 | 9 | 4 |
| Month 33, n=1202, 1199, 1128 | 5 | 7 | 8 |
| Month 36, n=1187, 1174, 1095 | 3 | 5 | 2 |
| Month 39, n=1160, 1144, 1055 | 7 | 8 | 5 |
| Month 42, n=1149, 1126, 1034 | 9 | 8 | 2 |
| Month 45, n=1129, 1110, 1009 | 6 | 8 | 5 |
| Month 48, n=1113, 1093, 990 | 1 | 3 | 1 |
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: "Has the participant had any unplanned GP/Urologist (outpatient) visits that would have taken place if a scheduled study visit had not been planned (this can include visits resulting from UTI, UI macroscopic haematuria, etc?". If the answer to the question was "yes," the number of visits was recorded.
| visits | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 3, n=1550, 1581, 1564 | 23 | 25 | 26 |
| Month 6, n=1479, 1517, 1514 | 23 | 34 | 22 |
| Month 9, n=1439, 1465, 1477 | 16 | 35 | 22 |
| Month 12, n=1400, 1431, 1434 | 30 | 29 | 34 |
| Month 15, n=1343, 1386, 1380 | 24 | 22 | 27 |
| Month 18, n=1318, 1350, 1328 | 21 | 25 | 26 |
| Month 21, n=1281, 1326, 1287 | 18 | 21 | 14 |
| Month 24, n=1263, 1293, 1244 | 10 | 19 | 21 |
| Month 27, n=1233, 1262, 1206 | 15 | 11 | 14 |
| Month 30, n=1222, 1221, 1166 | 7 | 8 | 10 |
| Month 33, n=1202, 1199, 1128 | 4 | 5 | 10 |
| Month 36, n=1187, 1174, 1095 | 5 | 4 | 7 |
| Month 39, n=1160, 1144, 1055 | 6 | 13 | 19 |
| Month 42, n=1149, 1126, 1035 | 4 | 8 | 12 |
| Month 45, n=1129, 1110, 1009 | 3 | 5 | 6 |
| Month 48, n=1113, 1093, 990 | 1 | 6 | 5 |
At each scheduled 13-week clinic visit post-randomization, the investigator was to record details of any health care utilization associated with unplanned visits to GP/Urologist. Responses to the following question were recorded: "Does the participant have any unscheduled GP/Urologist (outpatients) visits planned, not relating to the study (this can include visits resulting from UTI, UI, macroscopic haematuria, etc.?". If the answer to the question was "yes," the number of visits was recorded.
| visits | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 3, n=1550, 1581, 1564 | 27 | 27 | 30 |
| Month 6, n=1479, 1516, 1514 | 23 | 29 | 33 |
| Month 9, n=1439, 1465, 1477 | 12 | 27 | 26 |
| Month 12, n=1400, 1431, 1434 | 30 | 28 | 29 |
| Month 15, n=1343, 1386, 1381 | 19 | 28 | 32 |
| Month 18, n=1318, 1350, 1328 | 23 | 21 | 34 |
| Month 21, n=1281, 1326, 1287 | 20 | 27 | 26 |
| Month 24, n=1263, 1293, 1244 | 29 | 23 | 26 |
| Month 27, n=1233, 1262, 1206 | 13 | 12 | 16 |
| Month 30, n=1222, 1221, 1166 | 10 | 16 | 10 |
| Month 33, n=1202, 1199, 1128 | 6 | 13 | 20 |
| Month 36, n=1187, 1174, 1095 | 8 | 12 | 18 |
| Month 39, n=1160, 1144, 1055 | 12 | 10 | 18 |
| Month 42, n=1149, 1126, 1035 | 15 | 9 | 15 |
| Month 45, n=1129, 1110, 1009 | 5 | 7 | 8 |
| Month 48, n=1113, 1093, 990 | 7 | 4 | 8 |
The BII is a 4-item questionnaire, score range of 0 (best) to 12 (worst) for questions 1-3, and 0 (best) to 13 (worst) for question 4, that assesses the overall impact of BPH on a participant's general sense of well being and measures aspects of physical discomfort, worry, and bother, all of which can be affected by BPH and its symptoms. BII score = sum of questions 1-4. Change from baseline = Post-Baseline Value. Estimates are based on the adjusted (least squares) means from the general linear model: change from baseline BII = treatment + cluster + baseline BII.
| points on a scale | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 12 | -1.9 ± 0.06 | -1.5 ± 0.06 | -1.6 ± 0.06 |
| Month 24 | -2.1 ± 0.07 | -1.7 ± 0.07 | -1.5 ± 0.07 |
| Month 36 | -2.2 ± 0.07 | -1.8 ± 0.07 | -1.3 ± 0.07 |
| Month 48 | -2.2 ± 0.07 | -1.8 ± 0.07 | -1.2 ± 0.07 |
The effect of study treatment on BHS was assessed by using three self-administered questionnaires: the International Prostate Symptom Score (IPSS), the BPH Impact Index (BII), and Patient Perception of Study Medication (PPSM). The BHS score was collected on the IPPS questionnaire and ranged from 0 (best) to 6 (worst). Percent change from baseline = \[(post-baseline - baseline)/baseline value\] x 100. Estimates were based on the adjusted (least squares) means from the general linear model: change from baseline BPH-related health status = treatment + cluster + baseline BPH-Related health status.
| points on a scale | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Month 12 | -1.2 ± 0.03 | -1.0 ± 0.03 | -1.0 ± 0.03 |
| Month 24 | -1.4 ± 0.03 | -1.1 ± 0.03 | -1.1 ± 0.03 |
| Month 36 | -1.5 ± 0.03 | -1.2 ± 0.03 | -1.1 ± 0.03 |
| Month 48 | -1.5 ± 0.03 | -1.3 ± 0.03 | -1.1 ± 0.03 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has control of your urinary problems changed?".
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Improvement, n=1585, 1600, 1586 | 696 | 656 | 706 |
| BL, No Change/Any Worsening, n=1585, 1600, 1586 | 889 | 944 | 880 |
| Month (M) 12, Any Improvement, n=1576, 1593, 1581 | 1281 | 1171 | 1218 |
| M12, No Change/Any Worsening, n=1576, 1593, 1581 | 295 | 422 | 363 |
| M24, Any Improvement, n=1576, 1593, 1581 | 1273 | 1200 | 1195 |
| M24, No Change/Any Worsening, n=1576, 1593, 1581 | 303 | 393 | 386 |
| M36, Any Improvement, n=1576, 1593, 1581 | 1268 | 1203 | 1152 |
| M36, No Change/Any Worsening, n=1576, 1593, 1581 | 308 | 390 | 429 |
| M48, Any Improvement, n=1576, 1593, 1581 | 1278 | 1212 | 1138 |
| M48, No Change/Any Worsening, n=1576, 1593, 1581 | 298 | 381 | 443 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect of the study medication on control of your urinary problems?" Satisfact., satisfaction.
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Satisfact., n=1587, 1600, 1583 | 707 | 652 | 686 |
| BL, Neutral/Any Dissatisfact., n=1587, 1600, 1583 | 880 | 948 | 897 |
| Month (M) 12, Any Satisfact., n=1576, 1593, 1581 | 1224 | 1127 | 1178 |
| M12, Neutral/Any Dissatisfact., n=1576, 1593, 1581 | 352 | 466 | 403 |
| M24, Any Satisfact., n=1576, 1593, 1581 | 1261 | 1166 | 1150 |
| M24, Neutral/Any Dissatisfact., n=1576, 1593, 1581 | 315 | 427 | 431 |
| M36, Any Satisfact., n=1576, 1593, 1581 | 1260 | 1167 | 1120 |
| M36, Neutral/Any Dissatisfact., n=1576, 1593, 1581 | 316 | 426 | 461 |
| M48, Any Satisfact., n=1576, 1593, 1581 | 1267 | 1172 | 1088 |
| M48, Neutral/Any Dissatisfact., n=1576, 1593, 1581 | 309 | 421 | 493 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has the strength of your urinary stream changed?".
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Improvement, n=1585, 1601, 1585 | 629 | 602 | 615 |
| BL, No Change/Any Worsening, n=1585, 1601, 1585 | 956 | 999 | 970 |
| Month (M) 12, Any Improvement, n=1576, 1593, 158 | 1181 | 1044 | 1105 |
| M12, No Change/Any Worsening, n=1576, 1593, 1581 | 395 | 549 | 476 |
| M24, Any Improvement, n=1576, 1593, 1581 | 1215 | 1070 | 1057 |
| M24, No Change/Any Worsening, n=1576, 1593, 1581 | 361 | 523 | 524 |
| M36, Any Improvement, n=1576, 1593, 1581 | 1206 | 1071 | 1023 |
| M36, No Change/Any Worsening, n=1576, 1593, 1581 | 370 | 522 | 558 |
| M48, Any Improvement, n=1576, 1593, 1581 | 1202 | 1086 | 1008 |
| M48, No Change/Any Worsening, n=1576, 1593, 1581 | 374 | 507 | 573 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect of the study medication on the strength of your urinary stream?". Satisfact., satisfaction.
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Satisfact., n=1583,1601,1582 | 632 | 586 | 613 |
| BL, Neutral/Any Dissatisfact., n=1583,1601,1582 | 951 | 1015 | 969 |
| Month (M) 12, Any Satisfact., n=1576, 1593, 1581 | 1154 | 1037 | 1097 |
| M12, Neutral/Any Dissatisfact., n=1576, 1593, 1581 | 422 | 556 | 484 |
| M24, Any Satisfact., n=1576, 1593, 1581 | 1203 | 1072 | 1051 |
| M24, Neutral/Any Dissatisfact., n=1576, 1593, 1581 | 373 | 521 | 530 |
| M36, Any Satisfact., n=1576, 1593, 1581 | 1201 | 1075 | 1039 |
| M36, Neutral/Any Dissatisfact., n=1576, 1593, 1581 | 375 | 518 | 542 |
| M48, Any Satisfact., n=1576, 1593, 1581 | 1208 | 1089 | 1022 |
| M48, Neutral/Any Dissatisfact., n=1576, 1593, 1581 | 368 | 504 | 559 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has your pain prior to urinating changed?".
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Improvement, n=869, 901, 849 | 337 | 331 | 332 |
| BL, No Change/Any Worsening, n=869, 901, 849 | 532 | 570 | 517 |
| Month (M) 12, Any Improvement, n=769, 817, 771 | 556 | 526 | 527 |
| M12, No Change/Any Worsening, n=769, 817, 771 | 213 | 291 | 244 |
| M24, Any Improvement, n=720, 780, 771 | 537 | 526 | 535 |
| M24, No Change/Any Worsening, n=720, 780, 771 | 183 | 254 | 236 |
| M36, Any Improvement, n=714, 753, 748 | 540 | 514 | 496 |
| M36, No Change/Any Worsening, n=714, 753, 748 | 174 | 239 | 252 |
| M48, Any Improvement, n=709, 756, 751 | 531 | 510 | 489 |
| M48, No Change/Any Worsening, n=709, 756, 751 | 178 | 246 | 262 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your pain prior to urinating?". Satisfact., satisfaction.
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Satisfact., n=908, 932, 889 | 375 | 351 | 351 |
| BL, Neutral/Any Dissatisfact., n=908, 932, 889 | 533 | 581 | 538 |
| Month (M) 12, Any Satisfact., n=1022, 1088, 1019 | 712 | 672 | 681 |
| M12, Neutral/Any Dissatisfact., n=1022, 1088, 1019 | 310 | 416 | 338 |
| M24, Any Satisfact., n=1077, 1151, 1085 | 764 | 740 | 708 |
| M24, Neutral/Any Dissatisfact., n=1077, 1151, 1085 | 313 | 411 | 377 |
| M36, Any Satisfact., n=1115, 1200, 1135 | 799 | 785 | 736 |
| M36, Neutral/Any Dissatisfact., n=1115, 1200, 1135 | 316 | 415 | 399 |
| M48, Any Satisfact., n=1135, 1223, 1161 | 810 | 792 | 739 |
| M48, Neutral/Any Dissatisfact., n=1135, 1223, 1161 | 325 | 431 | 422 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has your pain during urination changed?".
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Improvement, n=852, 889, 822 | 321 | 314 | 319 |
| BL, No Change/Any Worsening, n=852, 889, 822 | 531 | 575 | 503 |
| Month (M) 12, Any Improvement, n=760, 781, 755 | 550 | 500 | 529 |
| M12, No Change/Any Worsening, n=760, 781, 755 | 210 | 281 | 226 |
| M24, Any Improvement, n=706, 760, 747 | 532 | 508 | 519 |
| M24, No Change/Any Worsening, n=706, 760, 747 | 174 | 252 | 228 |
| M36, Any Improvement, n=704, 741, 733 | 529 | 504 | 491 |
| M36, No Change/Any Worsening, n=704, 741, 733 | 175 | 237 | 242 |
| M48, No Change/Any Worsening, n=702, 739, 740 | 175 | 252 | 257 |
| M48, Any Improvement, n=702, 739, 740 | 527 | 487 | 483 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your pain during urination?". Satisfact., satisfaction.
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Satisfact., n=890, 925, 851 | 354 | 348 | 333 |
| BL, Neutral/Any Dissatisfact., n=890, 925, 851 | 536 | 577 | 518 |
| Month (M) 12, Any Satisfact., n=1022, 1088, 1011 | 712 | 655 | 678 |
| M12, Neutral/Any Dissatisfact., n=1022, 1088, 1011 | 310 | 433 | 333 |
| M24, Any Satisfact., n=1077, 1155, 1079 | 763 | 730 | 708 |
| M24, Neutral/Any Dissatisfact., n=1077, 1155, 1079 | 314 | 425 | 371 |
| M36, Any Satisfact., n=1121, 1206, 1131 | 807 | 784 | 724 |
| M36, Neutral/Any Dissatisfact., n=1121, 1206, 1131 | 314 | 422 | 407 |
| M48, Any Satsifact., n=1146,1224,1160 | 827 | 785 | 729 |
| M48, Neutral/Any Dissatisfact., n=1146, 1224, 1160 | 319 | 439 | 431 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Since you began taking the study medication, how has the way your urinary problems interfere with your ability to go about your usual activities changed?".
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Improvement, n=1574, 1599, 1575 | 509 | 481 | 494 |
| BL, No Change/Any Worsening, n=1574, 1599, 1575 | 1065 | 1118 | 1081 |
| Month (M) 12, Any Improvement, n=1575, 1593, 1580 | 1124 | 1027 | 1084 |
| M12, No Change/Any Worsening, n=1575, 1593, 1580 | 451 | 566 | 496 |
| M24, Any Improvement, n=1575, 1593, 1580 | 1146 | 1053 | 1049 |
| M24, No Change/Any Worsening, n=1575, 1593, 1580 | 429 | 540 | 531 |
| M36, Any Improvement, n=1575, 1593, 1580 | 1575 | 1593 | 1580 |
| M36, No Change/Any Worsening, n=1575, 1593, 1580 | 412 | 529 | 553 |
| M48, Any Improvement, n=1575, 1593, 1580 | 1148 | 1063 | 1008 |
| M48, No Change/Any Worsening, n=1575, 1593, 1580 | 427 | 530 | 572 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "How satisfied are you with the effect the study medication has on your ability to go about your usual activities without interference from your urinary problems?". Satisfact., satisfaction.
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Satisfact., n=1574, 1600, 1576 | 611 | 565 | 584 |
| BL, Neutral /Any Dissatisfact., n=1574, 1600, 1576 | 963 | 1035 | 992 |
| Month (M) 12, Any Satisfact., n=1575, 1593, 1580 | 1176 | 1073 | 1114 |
| M12, Neutral/Any Dissatisfact., n=1575, 1593, 1580 | 399 | 520 | 466 |
| M24, Any Satisfact., n=1575, 1593, 1580 | 1205 | 1116 | 1088 |
| M24, Neutral/Any Dissatisfact., n=1575, 1593, 1580 | 370 | 477 | 492 |
| M36, Any Satisfact., n=1575, 1593, 1580 | 1210 | 1098 | 1074 |
| M36, Neutral/Any Dissatisfact., n=1575, 1593, 1580 | 365 | 495 | 506 |
| M48, Any Satisfact., n=1575, 1593, 1580 | 1213 | 1123 | 1043 |
| M48, Neutral/Any Dissatisfact., n=1575, 1593, 1580 | 362 | 470 | 537 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Overall, how satisfied are you with the study medication and it's effect on your urinary problems?". Satisfact., satisfaction.
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline (BL), Any Satisfact., n=1573, 1598, 1574 | 717 | 683 | 699 |
| BL, Neutral/Any Dissatisfact., n=1573, 1598, 1574 | 856 | 915 | 875 |
| Month (M) 12, Any Satisfact., n=1574, 1592, 1581 | 150 | 1159 | 1202 |
| M12, Neutral/Any Dissatisfact., n=1574, 1592, 1581 | 324 | 433 | 379 |
| M24, Any Satisfact., n=1574, 1592, 1581 | 1279 | 1188 | 1163 |
| M24, Neutral/Any Dissatisfact., n=1574, 1592, 1581 | 295 | 404 | 418 |
| M36, Any Satisfact., n=1574, 1592, 1581 | 1270 | 1188 | 1119 |
| M36, Neutral/Any Dissatisfact., n=1574, 1592, 1581 | 304 | 404 | 462 |
| M48, Any Satifact., n=1574, 1592, 1581 | 1262 | 1182 | 1097 |
| M48, Neutral/Any Dissatisfact., n=1574, 1592, 1581 | 312 | 410 | 484 |
This 12-item questionnaire (PPSM) was developed by GlaxoSmithKline for use in this study and was designed to quantify the participant's perceptions and satisfaction with the effect of study treatment on control of their urinary symptoms at baseline and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, and 48. Participants were asked to respond to the question of "Would you ask your doctor for the medication you received in this study?".
| participants | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Baseline, Yes, n=1560, 1579, 1562 | 587 | 557 | 582 |
| Baseline, No/Not Sure, n=1560, 1579, 1562 | 973 | 1022 | 980 |
| Month 12, Yes, n=1574, 1592, 1581 | 972 | 920 | 970 |
| Month 12, No/Not Sure, n=1574, 1592, 1581 | 602 | 671 | 611 |
| Month 24, Yes, n=1574, 1592, 1581 | 1027 | 955 | 952 |
| Month 24, No/Not Sure, n=1574, 1592, 1581 | 547 | 636 | 629 |
| Month 36, Yes, n=1574, 1592, 1581 | 1031 | 956 | 915 |
| Month 36, No/Not Sure, n=1574, 1592, 1581 | 543 | 636 | 666 |
| Month 48, Yes, n=1574, 1592, 1581 | 1003 | 918 | 874 |
| Month 48, No/Not Sure, n=1574, 1592, 1581 | 571 | 674 | 707 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combination | — | 303/1,610 (18.8%) | 618/1,610 (38.4%) |
| Dutasteride 0.5 mg | — | 339/1,623 (20.9%) | 586/1,623 (36.1%) |
| Tamsulosin 0.4 mg | — | 348/1,611 (21.6%) | 590/1,611 (36.6%) |
| Event | Combination | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 21/1610 | 17/1623 | 25/1611 |
| Myocardial infarctionCardiac disorders | 16/1610 | 25/1623 | 20/1611 |
| Inguinal herniaGastrointestinal disorders | 4/1610 | 17/1623 | 11/1611 |
| Coronary artery diseaseCardiac disorders | 14/1610 | 14/1623 | 15/1611 |
| Angina pectorisCardiac disorders | 14/1610 | 14/1623 | 15/1611 |
| Urinary retentionRenal and urinary disorders | 2/1610 | 6/1623 | 15/1611 |
| Cerebrovascular accidentNervous system disorders | 11/1610 | 15/1623 | 8/1611 |
| PneumoniaInfections and infestations | 13/1610 | 10/1623 | 6/1611 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 9/1610 | 13/1623 | 11/1611 |
| Atrial fibrillationCardiac disorders | 11/1610 | 7/1623 | 9/1611 |
| Event | Combination | Dutasteride 0.5 mg | Tamsulosin 0.4 mg |
|---|---|---|---|
| Erectile dysfunctionReproductive system and breast disorders | 167/1610 | 147/1623 | 109/1611 |
| NasopharyngitisInfections and infestations | 134/1610 | 129/1623 | 149/1611 |
| HypertensionVascular disorders | 133/1610 | 147/1623 | 136/1611 |
| Back painMusculoskeletal and connective tissue disorders | 107/1610 | 88/1623 | 113/1611 |
| InfluenzaInfections and infestations | 77/1610 | 75/1623 | 83/1611 |
| Age, Continuous(years) | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| Mean | 66.0 ± 7.05 | 66.0 ± 6.99 | 66.2 ± 7.00 | 66.1 ± 7.01 |
| Gender(Participants) | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 |
| Male | 1610 | 1623 | 1611 | 4844 |
| Race/Ethnicity, Customized(participants) | Dutasteride 0.5 mg Plus Tamsulosin 0.4 mg | Dutasteride 0.5 mg | Tamsulosin 0.4 mg | Total |
|---|---|---|---|---|
| White | 1421 | 1433 | 1405 | 4259 |
| Black | 22 | 17 | 24 | 63 |
| Asian | 107 | 106 | 112 | 325 |
| American Hispanic | 44 | 48 | 55 | 147 |
| Unknown | 16 | 19 | 15 | 50 |
Showing the first 100 of 504 sites across 36 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2003, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2010, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dutasteride · Tamsulosin